BOULDER, Colo., Feb. 8, 2013 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the Leerink Swann Healthcare Conference in New York. The public is welcome to participate in the conference through a webcast on the Array BioPharma website.
(Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO)
Event: | Leerink Swann Healthcare Conference |
Presenter: | Ron Squarer, Chief Executive Officer |
Date: | Thursday, February 14, 2013 |
Time: | 8:00 a.m. Eastern Time |
Location: | The Waldorf Astoria, New York, NY |
Webcast: |
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. During 2013, Array expects to make substantial progress in generating data to inform registration study decisions for our wholly-owned hematology programs, ARRY-520 and ARRY-614. Array-invented MEK162 will be tested in a Phase 3 trial in NRAS melanoma which is scheduled to start in April 2013, as well as BRAF mutant melanoma later in 2013 (with Novartis). Also, AstraZeneca recently announced a potential start of a Phase 3 trial with Array-invented selumetinib in non-small cell lung cancer during the second half of 2013. For more information on Array, please go to www.arraybiopharma.com.
CONTACT: | Tricia Haugeto |
Array BioPharma Inc. | |
303-386-1193 | |
SOURCE Array BioPharma Inc.
